Preferred Label : Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010;
NCIt synonyms : PD-1/CTLA-4/VEGF Trispecific Antibody HC010;
NCIt definition : A trispecific antibody directed against the negative immunoregulatory human cell receptor
programmed cell death protein 1 (PD-1; PDCD1; CD279), the cytotoxic T-lymphocyte-associated
antigen 4 (CTLA4; CTLA-4), and the human vascular endothelial growth factor (VEGF),
with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities.
Upon administration, anti-PD-1/anti-CTLA-4/anti-VEGF trispecific antibody HC010 simultaneously
targets, binds to and blocks PD-1 and CTLA-4 expressed on tumor-infiltrating lymphocytes
(TILs) in the tumor microenvironment (TME), thereby inhibiting the PD-1- and CTLA-4-mediated
downregulation of T-cell activation and proliferation. This restores immune function
and enhances cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis, which may lead
to a reduction in tumor growth. The binding of HC010 to VEGF prevents binding of VEGF
to its receptor VEGFR, abrogates VEGF/VEGFR-mediated signaling and may lead to the
inhibition of vascular endothelial cell proliferation. The inhibition of tumor angiogenesis
may further decrease tumor cell proliferation and prevent metastasis. Both PD-1 and
CTLA-4 negatively regulate the activation and effector functions of T-cells. They
play key roles in the downregulation of the immune system and tumor evasion from host
immunity. Dual checkpoint blockade of PD-1 and CTLA-4 enhances T-cell activation and
proliferation more than the blockade of either immune checkpoint receptor alone. VEGF
is overexpressed in a variety of cancers and is associated with increased invasiveness
and decreased survival.;
Molecule name : HC-010; HC 010;
Origin ID : C212065;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
